RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for the development of six preclinical small interfering RNA (siRNA) therapies targeting metabolic dysfunction-associated steatohepatitis (MASH). Under the agreement, RIBOLIFE-B has granted Madrigal exclusive global rights to utilize its RiboGalSTAR™ platform and siRNA chemical modification technology to develop, manufacture, and commercialize certain preclinical single-target and dual-target siRNA assets. The group will receive an upfront payment of $60 million and could receive up to $4.4 billion in total upon achieving certain development, regulatory, and commercial milestones, in addition to potential royalties on net sales. As of the announcement date, milestone payments under the agreement are contingent on meeting specific conditions, and the final amount the company may receive remains uncertain. This collaboration will leverage RIBOLIFE-B’s proven liver-targeted RiboGalSTAR™ platform to develop new treatments for MASH, marking a significant milestone in the company’s journey to becoming a globally leading innovative siRNA enterprise. It also accelerates the company’s global development and commercialization strategy, aiming to deliver more targeted and effective therapies for unmet medical needs in MASH patients.